Even as an unsympathetic corporate defendant, Merck won the vast majority of cases that went to tria over Vioxxl, and another dozen or more that plaintiffs' attorneys dismissed on the eve of trial rather than risk the publicity of a certain loss.Yet the litigation still cost the company $7 billion.